325 related articles for article (PubMed ID: 27510350)
1. Osteoporosis treatment: a missed opportunity.
Milat F; Ebeling PR
Med J Aust; 2016 Aug; 205(4):185-90. PubMed ID: 27510350
[TBL] [Abstract][Full Text] [Related]
2. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic targets for osteoporosis.
Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis.
Compston JE; McClung MR; Leslie WD
Lancet; 2019 Jan; 393(10169):364-376. PubMed ID: 30696576
[TBL] [Abstract][Full Text] [Related]
5. New Frontiers in Osteoporosis Therapy.
Cheng C; Wentworth K; Shoback DM
Annu Rev Med; 2020 Jan; 71():277-288. PubMed ID: 31509477
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Therapy of Osteoporosis: What's New?
Iolascon G; Moretti A; Toro G; Gimigliano F; Liguori S; Paoletta M
Clin Interv Aging; 2020; 15():485-491. PubMed ID: 32273690
[TBL] [Abstract][Full Text] [Related]
7. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
8. Treatment of osteoporosis: whom, how and for how long?
Dede AD; Callan M
Br J Hosp Med (Lond); 2018 May; 79(5):259-264. PubMed ID: 29727238
[TBL] [Abstract][Full Text] [Related]
9. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
O'Hanlon CE; Parthan A; Kruse M; Cartier S; Stollenwerk B; Jiang Y; Caloyeras JP; Crittenden DB; Barron R
Clin Ther; 2017 Jul; 39(7):1276-1290. PubMed ID: 28629610
[TBL] [Abstract][Full Text] [Related]
10. [Male osteoporosis].
Farahmand P; Spiegel R; Ringe JD
Z Rheumatol; 2016 Jun; 75(5):459-65. PubMed ID: 27117306
[TBL] [Abstract][Full Text] [Related]
11. Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice.
Naik-Panvelkar P; Norman S; Elgebaly Z; Elliott J; Pollack A; Thistlethwaite J; Weston C; Seibel MJ
BMC Fam Pract; 2020 Feb; 21(1):32. PubMed ID: 32050909
[TBL] [Abstract][Full Text] [Related]
12. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.
Canalis E
Eur J Endocrinol; 2018 Feb; 178(2):R33-R44. PubMed ID: 29113980
[TBL] [Abstract][Full Text] [Related]
13. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Viswanathan M; Reddy S; Berkman N; Cullen K; Middleton JC; Nicholson WK; Kahwati LC
JAMA; 2018 Jun; 319(24):2532-2551. PubMed ID: 29946734
[TBL] [Abstract][Full Text] [Related]
14. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.
Hanley DA; McClung MR; Davison KS; Dian L; Harris ST; Miller PD; Lewiecki EM; Kendler DL;
Am J Med; 2017 Jul; 130(7):862.e1-862.e7. PubMed ID: 28359721
[TBL] [Abstract][Full Text] [Related]
15. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
16. New and developing pharmacotherapy for osteoporosis in men.
Gennari L; Bilezikian JP
Expert Opin Pharmacother; 2018 Feb; 19(3):253-264. PubMed ID: 29350069
[TBL] [Abstract][Full Text] [Related]
17. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
[TBL] [Abstract][Full Text] [Related]
19. Anabolic therapy for osteoporosis: update on efficacy and safety.
Bandeira L; Lewiecki EM
Arch Endocrinol Metab; 2022 Nov; 66(5):707-716. PubMed ID: 36382760
[TBL] [Abstract][Full Text] [Related]
20. Established and forthcoming drugs for the treatment of osteoporosis.
Lems WF; Geusens P
Curr Opin Rheumatol; 2014 May; 26(3):245-51. PubMed ID: 24625372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
